27th May 2009 15:00
Invitation to Comment
Anticipated joint venture between GlaxoSmithKline plc and Pfizer Inc IN RELATION TO THEIR RESPECTIVE HIV BUSINESSES
The Office of Fair Trading is considering whether arrangements are in progress or in contemplation which, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002. Should it be found to be a relevant merger situation, the OFT will further consider whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services that warrants reference to the Competition Commission for investigation and report.
Affected sector: Pharmaceuticals.
Please send written representations about any competition or public interest issues
to:
Carole Bowley
Office of Fair Trading
Fleetbank House
2-6 Salisbury Square
London EC4Y 8JX
Email: [email protected]
Fax: 020 7211 8916
to arrive by 9 June 2009.
Related Shares:
GlaxosmithklinePFZ.L